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Health-Related Quality of Life After Angioplasty and Stent
Placement in Patients With Iliac Artery Occlusive Disease
Results of a Randomized Controlled Clinical Trial
Johanna L. Bosch, PhD; Yolanda van der Graaf, MD, PhD; Maria G.M. Hunink, MD, PhD;
for the Dutch Iliac Stent Trial Study Group*
Backround—To assess the quality of life in patients with iliac artery occlusive disease, we compared primary stent
placement versus primary angioplasty followed by selective stent placement in a multicenter randomized controlled trial.
Methods and Results—Quality-of-life assessments were completed by 254 patients in a telephone interview. Assessment
measures consisted of the RAND 36-Item Health Survey 1.0, time tradeoff, standard gamble, rating scale, health utilities
index, and EuroQol-5D. The interviews were performed before treatment and after 1, 3, 12, and 24 months. When the 2
treatments were compared, no significant difference was observed (P.0.05). All measurements showed a significant
improvement in the quality of life after treatment (P,0.05). The RAND 36-Item Health Survey measures physical
functioning, role limitations caused by physical problems, and bodily pain and the EuroQol-5D were the most sensitive to the
impact of revascularization.
Conclusions—Health-related quality of life improves equally after primary stent placement and primary angioplasty with
selective stent placement in the treatment of intermittent claudication caused by iliac artery occlusive disease.
(Circulation. 1999;99:3155-3160.)
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Intermittent claudication caused by stenoses or occlusions inthe iliac arteries is a lifestyle-limiting condition. For the
majority of patients with intermittent claudication, the initial
treatment consists of risk factor modification and exercise
training. If initial noninterventional options fail and percutane-
ous intervention is feasible, patients are generally treated with
percutaneous transluminal angioplasty (PTA) and, more re-
cently, with stent placement. Stents can be placed as either a
primary or adjuvant therapy after suboptimal results are
achieved with PTA.1,2
In presenting the results of percutaneous interventions, inves-
tigators generally report initial hemodynamic and long-term
patency outcomes. Although these outcomes are of interest to
the physician, patients are concerned mainly with their walking
distance and quality of life. In the evaluation of interventions that
have little or no impact on long-term survival, such as in
peripheral percutaneous interventions, quality-of-life assessment
is essential to demonstrate effectiveness.3
The purpose of this study was to assess the impact of
percutaneous treatment on patients’ quality of life in the
treatment of intermittent claudication. In a randomized con-
trolled trial that compared stent placement with PTA,2 we
measured and compared quality-of-life outcomes.
Methods
Patients and Interviews
All patients with intermittent claudication or critical ischemia caused
by stenosis or occlusion in the iliac arteries and who were seen by
vascular surgery departments in 1 of 6 participating hospitals in the
Netherlands from November 1993 through November 1996 were
considered for enrollment in the Dutch Iliac Stent Trial (DIST). Two
hundred seventy-nine patients were enrolled and assigned to undergo
either primary stent placement (group 1, n5143) or primary PTA
(group 2, n5136) with selective stent placement for unsatisfactory
angioplasty results, which was defined as a residual transstenotic
mean pressure gradient of .10 mm Hg with vasodilatation. Ran-
domization was performed for each hospital with a computer-
generated randomization table to limit imbalances between treatment
assignments to 4. Given the nature of the procedure, patients and
physicians were not blinded to the assigned treatment. The study
protocol was approved by the institutional review boards of the
participating hospitals. All patients were informed of the treatment
background and procedures, and their written informed consent was
obtained. The treatment protocol remained unchanged throughout
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the study. Additional details in regard to the inclusion and exclusion
criteria and treatment protocol have been reported previously.2
Ninety-one percent of the patients participated in the quality-of-life
assessment (n5254). Nonparticipation was caused by logistical reasons
(ie, the time between enrollment in the study and the procedure was too
short to perform the interview or patients could not be reached by
telephone). Quality of life was assessed by telephone before treatment
and 1, 3, 12, and 24 months after treatment. Patients received the
questionnaire by mail before each interview. One-year follow-up results
were available in 198 (97%) of 204 patients eligible for follow-up.
Two-year follow-up results were obtained in 101 (94%) of 108 patients
eligible for follow-up. In 13 patients, no follow-up interviews were
performed because of logistical reasons (n53), noncompliance (n56),
or comorbidity (n54). The mean follow-up was 14.7 months (range, 3
to 24 months). The interviews were performed by 3 trained interviewers
who were blind to the subjects’ treatment assignments. The duration of
an interview was '30 minutes.
Clinical evaluation was performed before and 3, 12, and 24
months after the intervention and included treadmill exercises with
measurement of ankle-brachial index.
Quality-of-Life Measures
The interview consisted of a generic descriptive health-status mea-
sure, the RAND 36-Item Health Survey 1.0 (RAND-36),4 and
several evaluation measures, such as the time tradeoff, health utilities
index (HUI),5,6 rating scale, standard gamble, and EuroQol-5D.7,8 In
the questionnaire, all measures were presented in the above order and
in a written format. In the pilot feasibility study, intrainterviewer and
interinterviewer reproducibility and test-retest reliability of the
questionnaire were demonstrated in a similar patient group.9 In
addition, construct validity and reliability of the telephone-based
time-tradeoff and standard-gamble methods were demonstrated in
patients with peripheral arterial occlusive disease.10
The RAND-36, which is equivalent to the Medical Outcomes
Study Short Form 36,4,11 includes 8 health dimensions. For each
dimension, responses to items are summed and scores are converted
to a 0 to 100 scale, in which 100 indicates best functioning or well
being. With valuational measures, patients were assigned numerical
values or utilities according to their present state of health averaged
over the previous 4 weeks on a scale from 0.0 (death) to 1.0 (full
health comparable to healthy contemporaries).12 In the time-tradeoff
patients were asked how many months or years they would trade in
exchange for full health rather than living a full life expectancy in the
current health state.9 In the standard-gamble patients were asked
what risk of death they would willingly take to improve their current
state of health to full health.9 In the rating scale, we asked patients to
rate their current state of health on a scale from 0 to 100, in which
0 represented death and 100 represented full health.9
To assess preferences for health states from a societal perspective,
we included the HUI Mark I and EuroQol-5D.5–8,13 Both measures
provided a framework to describe health states in terms of attributes
and a model to estimate a community-based value for every health
state that can be identified in the classification scheme.
Data Analysis
Data were analyzed in accordance with the intention-to-treat principle.
This principle implies that values were assumed to be zero in the
analysis if a patient died during follow-up. The Kolmogorov-Smirnov
test was used to test the null hypothesis that a variable had an underlying
normal distribution. In our study, most variables were not normally
distributed. Therefore, we report the medians and the proportion of
patients with values that exceeded a population-based reference value.
For each measurement instrument, the reference value was defined as
the lower 95% confidence limit of published data from a similar age
group among the general population (Personal Communication, Sylvie
Alary [Technical Research Officer, National Health Population Survey,
Canada Statistics], e-mail, March 1998).11,14-16 In addition, the results
were compared with health values measured with the same question-
naire in a comparable group of patients with intermittent claudication
who participated in an exercise program (with a symptom-free walking
distance of 150 m).17
We tested for statistical significance of differences in quality-of-
life values before and after treatment, differences in proportions of
patients with values comparable to the reference values before and
after treatment, and differences in quality-of-life values between the
treatment groups with repeated-measures ANOVA (a50.05). The
statistical association of the change in ankle-brachial index and
walking distance with the change in physical functioning (RAND-
36) and bodily pain (RAND-36) and the valuational measures before
and 2 years after treatment was assessed with the Spearman
correlation coefficient. All analyses were performed with standard
statistical software (SPSS for Windows version 6.01, SPSS). To
demonstrate the degree of clinical improvement, we present figures
with the cumulative frequency distribution of patients with the
indicated quality-of-life score or higher (ie, better quality of life) at
baseline and at 2-year follow-up.
Results
Most patients were treated for intermittent claudication, and the
majority had an iliac artery stenosis (Table 1).2 The treatment
groups demonstrated no significant differences with respect to
descriptive variables, baseline quality-of-life measures, and
baseline clinical measures (Tables 1 to 6). In group 1, 143
patients (187 lesions) were treated with a total of 208 stents. In
group 2, 136 patients (169 lesions) were treated with PTA,
which was followed by selective stent placement in 59 patients
(43%; 65 lesions, 77 stents). Immediate postprocedural results
demonstrated that both groups yielded similar initial hemody-
namic success rates and complication rates (84% and 4% for
group 1 versus 88% and 7% for group 2, respectively).2 In
addition, 2-year cumulative patency rates, with patency defined
as a peak systolic velocity ratio of ,2.5 found at duplex
ultrasonography, were equivalent in both groups (ie, 71% and
70% for group 1 and group 2, respectively).2 Table 2 shows
mean ankle-brachial indices and walking distance over time. At
24-month follow-up, the proportion of patients with an ankle-
brachial index of $0.90 or an improvement of $0.15 compared
with pretreatment values was 80% when measured in rest and
92% when measured after exercise.
In both groups, scores of all RAND-36 dimensions showed
significant improvement after revascularization (Tables 3 and 4,
TABLE 1. Baseline Characteristics
Group 1, n5143 Group 2, n5136
Mean age, y (SD) 59 (11) 60 (10)
Male/female, n 102/41 99/37
Medical history, n (%)
Cerebrovascular accident 20 (14) 9 (7)
Diabetes mellitus 13 (9) 15 (11)
Hypertension 40 (28) 37 (27)
Tobacco use 124 (87) 128 (94)
No. of lesions 187 169
Arterial segment, n (%)
Common iliac artery 131 (70) 114 (67)
External iliac artery 56 (30) 55 (33)
Angiographic stenosis grade, n (%)
,50% diameter reduction 21 (11) 19 (11)
$50% diameter reduction 149 (80) 138 (82)
Total occlusion 17 (9) 12 (7)
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Figure 1). At 24-month follow-up, the scores were still signifi-
cantly higher than before treatment, with the exception of the
dimension of general health perception in group 1 (P50.20) and
group 2 (P50.09). The effect of treatment was highest for
physical functioning, physical role functioning, and bodily pain.
Figure 1 shows the cumulative distribution of patients who had
the indicated RAND-36 score or better. For example, Figure 1a
demonstrates that before revascularization, '18% of patients
had a score of $60 for physical functioning, whereas after
revascularization, this proportion increased to '68%. The pro-
portion of patients with values that exceeded the population
TABLE 2. Hemodynamic Data
Group 1 Group 2
Ankle-brachial index*
At rest
Before treatment 0.74 (0.20) 0.73 (0.21)
3 mo 0.92 (0.25) 0.93 (0.22)
12 mo 0.92 (0.22) 0.94 (0.19)
24 mo 0.88 (0.24) 0.96 (0.20)
After exercise
Before treatment 0.46 (0.23) 0.49 (0.23)
3 mo 0.80 (0.63) 0.81 (0.28)
12 mo 0.74 (0.32) 0.82 (0.27)
24 mo 0.77 (0.28) 0.91 (0.24)
Walking distance, m†
Before treatment 190 (109) 204 (106)
3 mo 263 (57) 255 (64)
12 mo 261 (58) 263 (65)
24 mo 258 (68) 255 (68)
Values are mean (SD).
*Mean of the ratio of minimum left/right ankle pressure and brachial blood
pressures.
†Measured during a 5-minute walking test with a maximum of 300 m.
TABLE 3. Median RAND-36 Scores at Baseline and During Follow-Up
Before
Revascularization
After Revascularization
1 mo 3 mo 12 mo 24 mo
Group 1
Physical functioning 40 (5–79) 85 (10–100) 85 (10–100) 70 (7–100) 75 (5–100)
Physical role functioning 0 (0–100) 75 (0–100) 100 (0–100) 100 (0–100) 75 (0–100)
Emotional role functioning 100 (0–100) 100 (0–100) 100 (0–100) 100 (0–100) 100 (0–100)
Social functioning 63 (0–100) 88 (13–100) 100 (14–100) 100 (0–100) 88 (0–100)
Bodily pain 45 (3–100) 80 (4–100) 90 (20–100) 78 (4–100) 78 (2–100)
General health perception 55 (15–94) 65 (16–100) 65 (15–100) 63 (15–100) 55 (2–99)
Mental health 76 (13–100) 80 (28–100) 84 (28–100) 80 (6–100) 80 (30–100)
Vitality 50 (6–95) 65 (15–100) 70 (15–100) 65 (12–100) 70 (15–100)
Group 2
Physical functioning 45 (10–85) 80 (15–100) 85 (10–100) 85 (20–100) 85 (5–100)
Physical role functioning 0 (0–100) 75 (0–100) 100 (0–100) 100 (0–100) 100 (0–100)
Emotional role functioning 67 (0–100) 100 (0–100) 100 (0–100) 100 (0–100) 100 (0–100)
Social functioning 75 (13–100) 88 (13–100) 88 (13–100) 88 (25–100) 94 (0–100)
Bodily pain 45 (0–99) 67 (0–100) 78 (10–100) 80 (22–100) 90 (20–98)
General health perception 55 (10–90) 60 (15–95) 60 (10–95) 65 (15–95) 60 (15–100)
Mental health 74 (20–100) 80 (24–100) 80 (28–100) 76 (30–100) 80 (24–100)
Vitality 50 (5–90) 65 (10–100) 70 (20–100) 65 (16–100) 60 (15–100)
Higher scores mean better functioning, fewer limitations, or less pain. Parenthetical values are 95% range.
TABLE 4. Proportion of Patients With RAND-36 Scores
Exceeding the Lower 95% Confidence Limit of RAND-36 Values
Among the General Population
Before
Revascularization,
%
After Revascularization, %
1 mo 3 mo 12 mo 24 mo
Group 1
Physical functioning 5 60 62 49 51
Physical role functioning 18 54 63 57 53
Emotional role functioning 50 64 69 60 66
Social functioning 30 56 66 60 59
Bodily pain 17 58 64 59 57
General health perception 42 54 52 50 43
Mental health 54 61 66 56 57
Vitality 33 57 62 52 59
Group 2
Physical functioning 9 56 63 66 60
Physical role functioning 28 53 61 65 67
Emotional role functioning 45 54 64 72 71
Social functioning 42 53 61 66 63
Bodily pain 17 48 58 58 69
General health perception 41 45 46 51 48
Mental health 50 56 63 57 63
Vitality 35 56 54 54 46
These values are based on comparisons with a similar age group.11
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reference was significantly higher after revascularization than
before (Table 4) on most dimensions and in both groups (ie,
except general health perception in group 1 [P50.07] and group
2 [P50.60] and social functioning in group 2 [P50.10]). Scores
on all RAND-36 dimensions were not significantly different
between the groups.
All valuational quality-of-life measures demonstrated a sig-
nificant improvement after treatment, with the exception of the
standard gamble (group 1, P50.35; group 2, P50.40; Tables 5
and 6, Figure 2). At 24-month follow-up, the values were still
significantly higher than before treatment, with the exception of
the standard gamble and the time tradeoff in group 1 (P50.35)
and group 2 (P50.08). The treatment effect was highest when
measured with the EuroQol-5D. The cumulative distribution
(Figure 2) of patients with the indicated value or higher demon-
strates, for example, that before revascularization ,10% of
patients had a EuroQol-5D value of $0.60, whereas 24 months
after treatment, this proportion had increased to 55%. The
proportion of patients with values that exceeded the population-
reference value was significantly higher after revascularization
than before on most valuational measures (ie, except the time
tradeoff in group 1 [P50.10] and the standard gamble in group
1 [P50.11] and group 2 [P50.24]). The values were not
significantly different between the groups.
Compared with the external patient group (ie, patients with
intermittent claudication who participated in an exercise pro-
gram17), patients in the trial had lower quality-of-life values
before revascularization and higher values after revasculariza-
tion. The proportion of trial patients before revascularization
Figure 1. Cumulative distribution curves of patients with indi-
cated RAND-36 score or higher (ie, better) for the health dimen-
sions physical functioning (A) and bodily pain (B) of patients
assigned to either primary stent placement (solid line) or primary
PTA followed by selective stent placement (dashed line) at
baseline and at 24-month follow-up.
TABLE 5. Median Values at Baseline and During Follow-Up
Before
Revascularization
After Revascularization
1 mo 3 mo 12 mo 24 mo
Group 1
Time tradeoff 0.88 (0.40–1.00) 0.94 (0.40–1.00) 0.96 (0.40–1.00) 0.98 (0.40–1.00) 0.93 (0.01–1.00)
Standard gamble 0.96 (0.40–1.00) 0.98 (0.51–1.00) 1.00 (0.50–1.00) 1.00 (0.50–1.00) 0.98 (0.02–1.00)
Rating scale 0.75 (0.29–0.96) 0.80 (0.50–1.00) 0.80 (0.40–1.00) 0.80 (0.40–1.00) 0.80 (0.28–1.00)
Health utilities index 0.68 (0.35–0.87) 0.70 (0.37–1.00) 0.76 (0.04–1.00) 0.70 (0.28–1.00) 0.70 (0.22–1.00)
EuroQol-5D 0.46 (0.20–0.75) 0.70 (0.15–1.00) 0.75 (0.15–1.00) 0.59 (0.19–1.00) 0.70 (0.09–1.00)
Group 2
Time tradeoff 0.88 (0.30–1.00) 0.91 (0.10–1.00) 0.96 (0.47–1.00) 0.95 (0.49–1.00) 0.95 (0.00–1.00)
Standard gamble 0.95 (0.48–1.00) 0.96 (0.47–1.00) 0.96 (0.51–1.00) 0.96 (0.40–1.00) 0.96 (0.00–1.00)
Rating scale 0.75 (0.20–0.99) 0.80 (0.50–1.00) 0.80 (0.50–1.00) 0.80 (0.40–1.00) 0.80 (0.40–1.00)
Health utilities index 0.69 (0.28–0.80) 0.70 (0.24–1.00) 0.70 (0.27–1.00) 0.77 (0.28–1.00) 0.70 (0.16–1.00)
EuroQol-5D 0.46 (0.15–0.75) 0.70 (0.20–1.00) 0.70 (0.20–1.00) 0.70 (0.15–1.00) 0.66 (0.15–1.00)
Parenthetical values are 95% range.
TABLE 6. Proportion of Patients With a Utility or Value
Exceeding the Lower 95% Confidence Limit of Values among
the General Population
Before
Revascularization,
%
After Revascularization, %
1 mo 3 mo 12 mo 24 mo
Group 1
Time tradeoff 58 71 70 71 65
Standard gamble 68 76 80 78 73
Rating scale 71 77 78 75 73
Health utilities index 0 15 19 14 15
EuroQol-5D 0 44 45 39 40
Group 2
Time tradeoff 56 69 74 76 60
Standard gamble 74 76 82 80 73
Rating scale 64 76 79 78 73
Health utilities index 0 17 18 22 25
EuroQol-5D 1 39 45 45 42
Values are based on comparisons with similar age groups.14–16
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with values below the 95% CI of the reference values among
patients who underwent exercise therapy ranged from 21%
(standard gamble) to 67% (RAND-36 physical functioning).
After revascularization, these proportions decreased signifi-
cantly. At 2-year follow-up, the proportion of trial patients after
revascularization with health values equal to or higher than the
upper 95% confidence limit of the reference values among
patients who underwent exercise therapy ranged from 62%
(EuroQol-5D) to 78% (RAND-36, bodily pain).
The Spearman correlation coefficient of changes from before
treatment to 2-year follow-up that compared hemodynamic data
with physical functioning (RAND-36) and bodily pain (RAND-
36) and valuational measures ranged from 20.11 (ie,
EuroQol-5D with ankle-brachial index after exercise) to 0.28 (ie,
physical functioning with ankle-brachial index at rest).
Discussion
Health-related quality of life was assessed in a randomized
controlled trial that compared primary stent placement and
primary PTA followed by selective stent placement. Results
demonstrated that both percutaneous treatment strategies
significantly improved patients’ quality of life. No significant
difference in quality-of-life outcomes was demonstrated be-
tween the groups. Immediate hemodynamic results and clin-
ical outcomes during follow-up were also similar in both
groups.2 Thus, costs rather than effectiveness may be the
decisive factor in the choice of percutaneous treatment.
Theoretically, it is possible that the outcomes were biased
because of the interviews or interviewers. A placebo effect
may have occurred because of the attention patients received
from the interviewer or because of a learning effect. How-
ever, the demonstrated improvements in quality of life are not
explainable with a placebo effect alone. In addition, previous
studies evaluated construct validity, reliability, and feasibility
of the measures in patients with peripheral arterial occlusive
disease, and the measures were shown to be valid.9,10 Second,
an order effect may have biased the quality-of-life values;
however, because the same order was used in both treatment
groups, a bias in the comparison between the groups was
eliminated by randomization across treatments. Furthermore,
a bias because of expectations of the interviewers is unlikely
because the interviewers were blind to the assigned treatment.
Unfortunately, reference values from the Dutch population
were not available for all instruments we used. Because quality-
of-life values may differ across countries, the proportion of
patients with values above the reference may have been overes-
timated or underestimated. In addition, bias may have occurred
because a few reference values were obtained from a different
version of a questionnaire than the version used in our study.
Because we used the same reference values in both treatment
groups, these biases did not influence the comparison between
the groups.
A limitation of our study was the limited follow-up, and it
thus remains unclear what the long-term efficacy, including
quality of life, may be after PTA and stent placement. Also, a
longer follow-up is needed to compare the outcomes with the
efficacy of other treatments with demonstrated long-term bene-
fits, such as exercise training or bypass surgery. Another
limitation of our study was that most patients had intermittent
claudication due to stenoses in the iliac arteries. The effect of
PTA and stent placement on health-related quality-of-life out-
comes in patients with critical ischemia caused by occlusions
remains to be elucidated. Another limitation was the omission of
a disease-specific questionnaire, such as the Walking Impair-
ment Questionnaire.18,19 Quality-of-life assessment in this trial
focused on valuational measures to enable a cost-effectiveness
analysis and included a generic health-status measure to describe
health on several dimensions. A disease-specific questionnaire
might have detected a small difference between the groups, but
given the large but equivalent effect sizes on the RAND-36
health dimensions physical functioning and bodily pain, a large
undetected difference seems unlikely.
As may be expected in the treatment of claudication, the
health dimensions of physical functioning and bodily pain were
the most sensitive to the impact of revascularization. Of the
valuational quality-of-life measures, the EuroQol-5D demon-
strated the highest treatment effect probably because it assesses
only 5 health dimensions, of which 1 is mobility. Although an
improvement in quality of life was demonstrated, many patients
still had low quality-of-life values compared with a general-
population reference group after treatment. The reason probably
is that revascularization in patients with atherosclerotic disease
does not cure the disease but rather is an attempt to improve
symptoms. In addition, atherosclerosis is a systemic disease, and
many patients may have had other manifestations of atheroscle-
rosis, such as angina pectoris. Another outcome of our study was
that at 2 years after revascularization, most patients demon-
strated higher quality-of-life values than a comparable group of
Figure 2. Cumulative distribution curves of patients with indi-
cated value or higher (ie, better) for the HUI (A) and EuroQol-5D
(B). Values indicate patients assigned to either primary stent
placement (solid line) or primary PTA followed by selective stent
placement (dashed line) at baseline and at 24-month follow-up.
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patients who participated in an exercise program, although
before treatment, the quality-of-life values were similar or
worse.17 Although we did not randomize between percutaneous
revascularization and exercise, the large improvement in quality-
of-life among the trial patients suggests that the revascularization
procedure was efficacious. Finally, our study demonstrated a
poor correlation between quality-of-life outcomes and hemody-
namic data. This suggests that measurement of clinical param-
eters alone has limitations and measurement of health-related
quality of life may provide extra information and is therefore
important to include in clinical trials in addition to functional and
clinical measures.
To the best of our knowledge, the results of quality-of-life
assessments after stent placement have not been reported previ-
ously. A few studies have reported the effect of PTA on
health-related quality of life and used measures such as the
RAND-36 and EuroQol-5D.20–22 The results of these studies
also demonstrated an improvement in quality of life after
treatment. In addition, these studies reported quality of life
measured at 1 point in time after revascularization. We included
measurement of quality of life at 4 points during follow-up and
found that most measures did not demonstrate a significant
decrease to baseline values, although a trend could be seen.
Additional research that analyzes long-term results is necessary
to demonstrate the long-term effect of PTA and stent placement.
In conclusion, in the treatment of intermittent claudication
caused by stenoses in the iliac arteries, health-related quality
of life improves equally after primary stent placement and
primary PTA, followed by selective stent placement. In
addition, a recently performed cost-effectiveness analysis
demonstrated that PTA with selective stent placement was a
cost-effective treatment strategy compared with primary stent
placement and with PTA alone.23 These results suggest that in
the treatment of intermittent claudication due to iliac artery
stenoses, the preferred treatment choice is primary PTA
followed by selective stent placement.
Appendix
Centers That Participated in the Dutch Iliac Stent
Trial Study Group
St Antonius Hospital Nieuwegein: TTC Overtoom, MD; JC de Valois,
MD, PhD (radiology); FL Moll, MD, PhD; HDWM van de Pavoordt,
MD, PhD (vascular surgery). Slingeland Hospital Doetinchem: JH
Spithoven, MD (radiology); JGJM van Iersel, MD; J Seegers, MD
(vascular surgery). University Hospital Utrecht: BC Eikelboom, MD,
PhD (vascular surgery); WPTM Mali, MD, PhD; JPJ van Schaik, MD,
PhD; FJA Beek, MD, PhD; E Tetteroo, MD, PhD; C Haaring, BA; and
AD van Engelen, MD (radiology). University Hospital, Rotterdam: H
Pieterman, MD, (radiology); H van Urk, MD, PhD (vascular surgery).
Twenteborg Hospital, Almelo: JJ Kouwenberg, MD; FHB Tuynman,
MD (radiology); JW van den Heuvel, MD; and JG van Baal, MD, PhD
(vascular surgery). Catharina Hospital, Eindhoven: GHM Landman,
MD, PhD; AV Tielbeek, MD, PhD (radiology); and J Buth, MD, PhD
(vascular surgery). University of Groningen: EEE van Wijck, MSc
(health sciences).
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